Overview

A Phase II Study of Neoadjuvant FOLFIRINOX

Status:
Active, not recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.

Phase:

Phase 2

Details

Lead Sponsor:

Indiana University
Safi Shahda

Treatments:

Folfirinox
Irinotecan
Leucovorin
Oxaliplatin